Bicara Therapeutics Inc

BCAX remains in a Stage 2 advancing uptrend despite the recent corrective leg, with price pulling back below the 9/21 EMAs but holding above the rising 50/200 DMAs. The medium-term bias stays bullish, and execution will await shallow pullback acceptance at the short-EMA zone. Key risks include deeper correction and failure to hold EMA support, which could signal a transition toward Stage 3.

• ↑Fisera delivered median overall survival of 21.3 months vs 6.7 months standard care
• ↑$539.8 M cash balance provides funding through H1 2029
• ↓Operating expenses jumped 45% YoY to $112.8 M, elevating leverage risk